Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Trials

29 clinical trials for Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial — RECRUITING · PHASE2
• mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma — RECRUITING · PHASE3
• Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence — RECRUITING · PHASE2
• Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer — RECRUITING · PHASE3
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors — RECRUITING · PHASE1
• Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma — RECRUITING · PHASE2
• Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma — RECRUITING · PHASE2
• Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer — RECRUITING · PHASE2
• CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors — RECRUITING · PHASE2
• Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer — COMPLETED · PHASE1
• Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery — SUSPENDED · PHASE2
• Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines — ACTIVE_NOT_RECRUITING · PHASE1
• A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study — NOT_YET_RECRUITING
• Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery — ACTIVE_NOT_RECRUITING · PHASE1
• Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial — ACTIVE_NOT_RECRUITING · PHASE1
• Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma — NOT_YET_RECRUITING · PHASE1
• Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial — NOT_YET_RECRUITING · NA
• Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study — COMPLETED
• Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma — COMPLETED · PHASE2
• Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers — WITHDRAWN · PHASE1

Refine this search